GLP-1 (Glucagon-Like Peptide-1) medications mimic an incretin hormone that targets the brain's appetite control center, reduces hunger, and slows stomach emptying
Peak Wellness serves patients in all 50 states
The addition of multiple GLP-1 receptor agonists to the National Reimbursement Drug List (NRDL) as part of Chinese government negotiations in 2019-2022 greatly enhanced access to these drugs, lowering the out-of-pocket cost by 60-80% and putting the drug into 200-300% use in 12-18 months of listing
More independent studies from a public health perspective are needed." The reviews highlight the need for long-term, independent investigations to guide clinical and policy decisions and to better define the role of GLP-1 receptor agonists in lasting weight management
Symptoms typically begin between 20 and 40 years of age
GLP-1 medications are designed to help you feel fuller for longer, which often results in a reduced appetite and lower calorie intake